ShockWave Medical Inc (SWAV) Q4 2020 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble.
ShockWave Medical Inc (NASDAQ: SWAV)
Q4 2020 Earnings Call
Good afternoon, and welcome to ShockWave s fourth-quarter and year-end 2020 earnings conference call. [Operator instructions] As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Debbie Kaster, vice president of investor relations at Shockwave for a few introductory comments.
Debbie Kaster
Vice President, Investor Relations
Thank you all for participating in today s call. Joining me today from Shockwave Medical are Doug Godshall, president and chief executive officer; Isaac Zacharias, chief commercial officer; and Dan Puckett, chief financial officer. Earlier today, Shockwave released financial results for the quarter and year ended December 31st, 2020. A copy of the press release is available on
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), ADVAXIS INC (ADXS) - The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Adaptimmune Therapeutics PLC (NYSE:ADAP) - The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Shockwave Intravascular Lithotripsy FDA Approved to Treat Advanced Heart Disease Transformative Technology Now Available for Calcified Coronary Plaque
February 16, 2021 07:00 ET | Source: Shockwave Medical, Inc. Shockwave Medical, Inc. Santa Clara, California, UNITED STATES
SANTA CLARA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company’s sonic pressure wave therapy received Pre-Market Approval for severely calcified coronary artery disease from the U.S. Food and Drug Administration (FDA). The innovative technology, which was granted Breakthrough Device designation by the FDA, is a novel application of lithotripsy, an approach that has been used for decades to safely break up kidney stones. With this approval, IVL is now commercially av
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (AVNS) - The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.